Alesi Surgical Limited, a Cardiff, UK-based provider of minimally invasive surgery technologies, raised a further €6m (£5.2m) funding.
Backers included Panakes Partners and Earlybird and existing shareholders IP Group plc and Finance Wales Limited. As part of the investment, Mr Thom Rasche, Partner at Earlybird and previously Vice President Europe of Ethicon Endosurgery, and Mr Alessio Beverina, Founding Partner at Panakes Partners, will both join the board of Alesi as investor directors. Non-executive director Phil Cooper, previously President at Molnlycke Healthcare, will join the board as well.
Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), and led by Dr Dominic Griffiths, Managing Director, Alesi Surgical develops and commercializes products that improve the safety, efficiency and outcomes of advanced surgical procedures.
The funds have been raised following the recent approval of the company’s proprietary technology platform, UltravisionTM, by both the US FDA (Food and Drug Administration) and Japanese Ministry of Health, and the commercial traction it is already gaining in already approved markets in Europe and the Middle East. The UltravisionTM system represents the world’s first use of electrostatic technology to clear the vapour and particulate matter – so called “surgical smoke” – that is generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery.
The company now intends to use the funds to drive commercial expansion of both Alesi Surgical and Ultravision into the United States and other key markets worldwide, and to undertake additional research and development around the new Ultravision technology.
Alesi Surgical is based at Cardiff Medicentre, the dedicated medical, healthcare, and life sciences business incubator located on the University Hospital of Wales campus.